Angiotensin receptor blockers for heart failure
88 results
1 - 88
Angiotensin receptor blockers for heart failure
Angiotensin receptor blockers for heart failure - Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction
- Chronic heart failure
- LCZ696 (sacubitril/valsartan) for patients with heart failure
- Heart failure nurse-led titration of heart failure medicines
- Angiotensin receptor blockers or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation
SGLT2 inhibitors optimal drug class for heart failure with preserved and mildly reduced ejection fraction- Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease
- Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction
- ACE inhibitor preferred over ARB in patients with ischemic heart disease
- ARB treatment of high CV risk patients
- Valsartan/sacubitril reduces mortality more than enalapril 10 mg twice daily in patients with heart failure (PARADIGM-HF)
- Drugs for chronic heart failure with preserved ejection fraction
- Diagnosing and managing acute heart failure Guidelines: NICE
- First‐line diuretics versus other classes of antihypertensive drugs for hypertension
- Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients
- Hypertrophic cardiomyopathy
- ACE inhibitors and angiotensin II receptor blockers for diabetics with microalbuminuria
- Guideline for the management of heart failure: early prevention for patients at risk, quadruple therapy for those with symptoms
- Calcium channel blockers versus other classes of drugs for hypertension
- ACE inhibitors decrease cardio events in patients with diabetes, ARBs don't
- First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension: Cochrane systematic review
- Eplerenone reduces mortality in NYHA II heart failure
- For patients with AMI and preserved ejection fraction, long-term beta-blockers do not improve outcomes (REDUCE-AMI)
- Drug treatment for hypertension
- Renin inhibitors versus angiotensin receptor blockers for primary hypertension
- Dilated cardiomyopathy
- Choice of prophylactic medication for atrial fibrillation - Image
- No improved patient-oriented outcomes with sacubitril/valsartan in adults with heart failure and preserved EF (PARALLAX)
- Finerenone decreases hospitalization for heart failure in patients with type 2 diabetes and chronic kidney disease (NNT = 189/year)
- Hypertension in elderly patients
- Acute coronary syndrome
- Digitalis for treatment of heart failure in patients in sinus rhythm
- First-line renin angiotensin system inhibitors versus other drug classes for hypertension
- Beta-blockers in patients without heart failure after myocardial infarction
- Bedtime instead of morning ingestion of hypertension meds = significantly more reduction in cardiovascular disease risk
- Pharmacological interventions for heart failure in people with chronic kidney disease
- Compliance with heart failure performance measures not associated with improved outcomes
- No differences in postoperative deaths or complications with stopping or continuing renin-angiotensin system inhibitors
- Antihypertensive agents for preventing diabetic kidney disease
- ACE inhibitors and angiotensin receptor blockers for progression of non-diabetic renal disease
- Finerenone reduces composite cardiovascular outcome and risk of decreased eGFR, but increases risk of hyperkalemia
- Aldosterone receptor antagonists spironolactone and eplerenone for congestive heart failure
- JNC 8 report on prevention/evaluation/treatment of hypertension
- Different antihypertensive agents as first line therapies
- Acute kidney injury
- Perioperative angiotensin‐converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults
- Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease
- Chronic diseases and pregnancy
- Dapagliflozin reduces mortality and renal replacement in patients with chronic kidney disease
- Rhythm control no better than rate control in AF + CHF
- Choice of antihypertensive drug in the diabetic patient from prognostic point of view
- Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks: Cochrane systematic review
- Irbesartan slows aortic dilation, but doesn't reduce the rate of surgery in those with Marfan syndrome (AIMS)
- Antihypertensive therapy beneficial for patients with BP < 140/90 and history of CVD
- Ventricular tachycardia
- BP target of 120 no better than 140 in T2DM (ACCORD)
- Higher blood pressure targets for hypertension in older adults
- Secondary hypertension
- Leg oedema
- SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
- Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure
- The most common types of acquired adult valvular heart disease and associated murmurs
- Treatment of chronic renal failure
- Use of medication during pregnancy